Original Article

You have full text access to this OnlineOpen article

Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density

  1. Henry G Bone1,*,
  2. Michael R McClung2,
  3. Christian Roux3,
  4. Robert R Recker4,
  5. John A Eisman5,
  6. Nadia Verbruggen6,
  7. Carolyn M Hustad7,
  8. Carolyn DaSilva7,
  9. Arthur C Santora7,
  10. B Avery Ince7

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.091035

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 5, pages 937–947, May 2010

Additional Information

How to Cite

Bone, H. G., McClung, M. R., Roux, C., Recker, R. R., Eisman, J. A., Verbruggen, N., Hustad, C. M., DaSilva, C., Santora, A. C. and Ince, B. A. (2010), Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J Bone Miner Res, 25: 937–947. doi: 10.1359/jbmr.091035

Author Information

  1. 1

    Michigan Bone and Mineral Clinic, Detroit, MI, USA

  2. 2

    Oregon Osteoporosis Center, Portland, OR, USA

  3. 3

    Paris Descartes University, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France

  4. 4

    School of Medicine, Creighton University, Omaha, NE, USA

  5. 5

    Garvan Institute of Medical Research, St Vincent's Hospital and UNSW, Sydney, NSW, Australia

  6. 6

    Merck Research Laboratories, Brussels, Belgium

  7. 7

    Merck Research Laboratories, Rahway, NJ, USA

*Michigan Bone and Mineral Center, 22201 Moross Road, Suite 260, Detroit, MI 48236, USA.

Publication History

  1. Issue published online: 30 APR 2010
  2. Article first published online: 14 DEC 2009
  3. Accepted manuscript online: 27 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 22 OCT 2009
  5. Manuscript Revised: 12 AUG 2009
  6. Manuscript Received: 14 APR 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (276K)

References

  • 1
    Yasuda Y, Kaleta J, Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005; 57: 973–993.
  • 2
    Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des. 2007; 13: 387–403.
  • 3
    Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther. 2008; 83: 172–176.
  • 4
    Adami S, Supronik J, Hala T, et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density (BMD) in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res. 2006; 21: S24.
  • 5
    Papanastasiou P, Ortmann CE, Olson M, Vigneron A, Trechsel U. Effect of three month treatment with the cathepsin-K inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women: evidence for uncoupling of bone resorption and bone formation. J Bone Miner Res. 2006; 21: S59.
  • 6
    Peroni A, Zini A, Braga V, Colato C, Adami S, Girolomoni G. Drug-induced morphea: Report of a case induced by balicatib and review of the literature. J Am Acad Dermatol. 2008; 59: 125–129.
  • 7
    Kumar S, Dare L, Vasko-Moser JA, et al. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys. Bone. 2007; 40: 122–131.
  • 8
    Bone HG, McClung M, Verbruggen N, et al. A randomized, double-blind, placebo-controlled study of a cathepsin-K inhibitor in the treatment of postmenopausal women with osteoporosis: One year results. J Bone Miner Res. 2007; 22 (suppl 1): S37.
  • 9
    Falgueyret JP, Desmarais S, Oballa R, et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J Med Chem. 2005; 48: 7535–7543.
  • 10
    Desmarais S, Black WC, Oballa R, et al. Effect of cathepsin K inhibitor basicity on in vivo off-target activities. Mol Pharmacol. 2008; 73: 147–156.
  • 11
    Yamashita DS, Marquis RW, Xie R, et al. Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitors. J Med Chem. 2006; 49: 1597–1612.
  • 12
    Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett. 2008; 18: 923–928.
  • 13
    Stoch S, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther. 2009; 86: 175–182.
  • 14
    Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zolendronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008; 23: 6–16.
    Direct Link:
  • 15
    Quan H, Luo X, Capizzi T. Multiplicity adjustment for multiple endpoints in clinical trials with multiple doses of an active treatment. Stat Med. 2005; 24: 2151–2170.
    Direct Link:
  • 16
    Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Statis Assoc. 1927; 22: 209–212.
  • 17
    Karsdal MA, Martin TJ, Bollerslev J, Christiansen C, Henriksen K. Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res. 2007; 22: 487–494.
    Direct Link:
  • 18
    Leung P, Zhou Y, Masarachia P, et al. 2008. Effects of the cathepsin K inhibitor odanacatib on osteoclast-mediated bone resorption. Presented at the 30th annual meeting of the American Society for Bone and Mineral Research, Montreal, Quebec, Canada, September 12–16, 2008, poster M127, online abstract book p. S405 (http://www.asbmr.org/secure/FINAL_Abstract_Book.pdf).
  • 19
    Atley LM, Mort JS, Lalumiere M, Eyre DR. Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone. 2000; 26: 241–247.
  • 20
    Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. 2003; 18: 859–867.
    Direct Link:
  • 21
    Apone S, Lee MY, Eyre DR. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone. 1997; 21: 129–136.
  • 22
    Bonnick S, Saag KG, Kiel DP, et al. for the FOSAMAX® ACTONEL® Comparison Trial (FACT) investigators Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab. 2006; 91: 2631–2367.
  • 23
    Reid DM, Hosking D, Kendler D, et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-international. Int J Clin Pract. 2008; 62: 575–584.
    Direct Link:
  • 24
    Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK. Tartrate-resistant acid phosphatase 5b: A novel serum marker of bone resorption. J Bone Miner Res. 2000; 15: 1337–1345.
    Direct Link:
  • 25
    Uusi-Rasi K, Kannus P, Cheng S, et al. Effect of alendronate and exercise on bone and physical performance of postmenopausal women: A randomized controlled trial. Bone. 2003; 33: 132–143.
  • 26
    Nenonen A, Cheng S, Ivaska KK, et al. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res. 2005; 20: 1804–1812.
    Direct Link:
View Full Article (HTML) Get PDF (276K)